{"transactions":[{"id":1615070,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Restricted Stock Unit","published_at":"2024-02-27T22:00:22.000Z","date":"2024-02-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024."}],"balance_after":3750,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001104659-24-028269","document":"tm247055-24_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465924028269/tm247055-24_4seq1.xml","form_type":"4"}},{"id":1615069,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2024-02-27T22:00:22.000Z","date":"2024-02-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":485,"price":29.06,"value":14094.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting."}],"balance_after":86933,"source":{"system":"sec-edgar","filing":"0001104659-24-028269","document":"tm247055-24_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465924028269/tm247055-24_4seq1.xml","form_type":"4"}},{"id":1615068,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2024-02-27T22:00:22.000Z","date":"2024-02-23","kind":"grant","planned":false,"acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":87418,"source":{"system":"sec-edgar","filing":"0001104659-24-028269","document":"tm247055-24_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465924028269/tm247055-24_4seq1.xml","form_type":"4"}},{"id":1618887,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Restricted Stock Units","published_at":"2024-02-26T22:00:21.000Z","date":"2024-02-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023."}],"balance_after":1500,"derivative":{"underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001104659-24-027564","document":"tm247055-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465924027564/tm247055-2_4seq1.xml","form_type":"4"}},{"id":1618886,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2024-02-26T22:00:21.000Z","date":"2024-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":246,"price":27.94,"value":6873.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting."}],"balance_after":86168,"source":{"system":"sec-edgar","filing":"0001104659-24-027564","document":"tm247055-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465924027564/tm247055-2_4seq1.xml","form_type":"4"}},{"id":1618885,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2024-02-26T22:00:21.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":86414,"source":{"system":"sec-edgar","filing":"0001104659-24-027564","document":"tm247055-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465924027564/tm247055-2_4seq1.xml","form_type":"4"}},{"id":1679836,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-01-12T22:00:24.000Z","date":"2024-01-10","kind":"exercise","planned":true,"acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested in four equal annual installments beginning on January 21, 2015."}],"balance_after":0,"derivative":{"exercise_price":9.24,"expiration_date":"2024-01-21","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001104659-24-003741","document":"tm243247-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465924003741/tm243247-1_4seq1.xml","form_type":"4"}},{"id":1679835,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2024-01-12T22:00:24.000Z","date":"2024-01-10","kind":"sale","planned":true,"acquired":false,"shares":8000,"price":27.91,"value":223280.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.69 to $28.22, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":85664,"source":{"system":"sec-edgar","filing":"0001104659-24-003741","document":"tm243247-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465924003741/tm243247-1_4seq1.xml","form_type":"4"}},{"id":1679834,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2024-01-12T22:00:24.000Z","date":"2024-01-10","kind":"exercise","planned":true,"acquired":true,"shares":8000,"price":9.24,"value":73920.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 415 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan."}],"balance_after":93664,"source":{"system":"sec-edgar","filing":"0001104659-24-003741","document":"tm243247-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465924003741/tm243247-1_4seq1.xml","form_type":"4"}},{"id":1790654,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-09-01T21:00:22.000Z","date":"2023-08-30","kind":"exercise","planned":false,"acquired":false,"shares":8100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal annual installments beginning on February 21, 2021."}],"balance_after":13900,"derivative":{"exercise_price":23.99,"expiration_date":"2030-02-21","underlying":"Common Stock","underlying_shares":8100},"source":{"system":"sec-edgar","filing":"0001104659-23-097813","document":"tm2325321-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923097813/tm2325321-1_4seq1.xml","form_type":"4"}},{"id":1790653,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2023-09-01T21:00:22.000Z","date":"2023-08-30","kind":"sale","planned":false,"acquired":false,"shares":8100,"price":32,"value":259200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.01, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":85249,"source":{"system":"sec-edgar","filing":"0001104659-23-097813","document":"tm2325321-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923097813/tm2325321-1_4seq1.xml","form_type":"4"}},{"id":1790652,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2023-09-01T21:00:22.000Z","date":"2023-08-30","kind":"exercise","planned":false,"acquired":true,"shares":8100,"price":23.99,"value":194319.0,"ownership":{"direct":true},"balance_after":93349,"source":{"system":"sec-edgar","filing":"0001104659-23-097813","document":"tm2325321-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923097813/tm2325321-1_4seq1.xml","form_type":"4"}},{"id":1794044,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2023-08-29T21:00:48.000Z","date":"2023-08-25","kind":"sale","planned":false,"acquired":false,"shares":5135,"price":31.59,"value":162214.65,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.38 to $31.92, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 350 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan."}],"balance_after":85249,"source":{"system":"sec-edgar","filing":"0001104659-23-096582","document":"tm2325057-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923096582/tm2325057-1_4seq1.xml","form_type":"4"}},{"id":1920801,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Restricted Stock Units","published_at":"2023-04-12T21:00:25.000Z","date":"2023-02-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023."}],"balance_after":2250,"derivative":{"underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001104659-23-044664","document":"tm2312277-2_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923044664/tm2312277-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2023-02-24"}},{"id":1920800,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2023-04-12T21:00:25.000Z","date":"2023-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":289,"price":38.57,"value":11146.73,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting."}],"balance_after":90034,"source":{"system":"sec-edgar","filing":"0001104659-23-044664","document":"tm2312277-2_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923044664/tm2312277-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2023-02-24"}},{"id":1920799,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2023-04-12T21:00:25.000Z","date":"2023-02-22","kind":"grant","planned":false,"acquired":true,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 853 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan."}],"balance_after":90323,"source":{"system":"sec-edgar","filing":"0001104659-23-044664","document":"tm2312277-2_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923044664/tm2312277-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2023-02-24"}},{"id":1989866,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Restricted Stock Units","published_at":"2023-02-27T22:03:01.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 23, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 23, 2024."}],"balance_after":5000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-23-026085","document":"tm237737-18_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923026085/tm237737-18_4seq1.xml","form_type":"4"}},{"id":1989865,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-02-27T22:03:01.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in four equal annual installments beginning on February 23, 2024."}],"balance_after":20000,"derivative":{"exercise_price":38.6,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-23-026085","document":"tm237737-18_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923026085/tm237737-18_4seq1.xml","form_type":"4"}},{"id":1992627,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Restricted Stock Units","published_at":"2023-02-24T22:02:30.000Z","date":"2023-02-22","kind":"disposition_to_issuer","acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023."}],"balance_after":2250,"derivative":{"underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001104659-23-025370","document":"tm237737-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923025370/tm237737-8_4seq1.xml","form_type":"4"}},{"id":1992626,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2023-02-24T22:02:30.000Z","date":"2023-02-22","kind":"grant","acquired":true,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 853 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan."}],"balance_after":90323,"source":{"system":"sec-edgar","filing":"0001104659-23-025370","document":"tm237737-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923025370/tm237737-8_4seq1.xml","form_type":"4"}},{"id":2003012,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Performance Share Unit","published_at":"2023-02-21T22:01:54.000Z","date":"2023-02-16","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On April 30, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period."}],"balance_after":0,"derivative":{"exercise_price":0,"expiration_date":"2031-04-30","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001104659-23-023834","document":"tm237193-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923023834/tm237193-3_4seq1.xml","form_type":"4"}},{"id":2003011,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2023-02-21T22:01:54.000Z","date":"2023-02-16","kind":"exercise","acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on April 30, 2021."}],"balance_after":88720,"source":{"system":"sec-edgar","filing":"0001104659-23-023834","document":"tm237193-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923023834/tm237193-3_4seq1.xml","form_type":"4"}},{"id":2053583,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Performance Share Unit","published_at":"2023-01-17T22:02:19.000Z","date":"2023-01-12","kind":"grant","acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On April 30 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period."}],"balance_after":1500,"derivative":{"exercise_price":0,"expiration_date":"2031-04-30","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001104659-23-004289","document":"tm233672-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465923004289/tm233672-2_4seq1.xml","form_type":"4"}},{"id":2175937,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-23T21:16:08.000Z","date":"2022-08-22","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested in four equal annual installments beginning on February 5, 2014."}],"balance_after":0,"derivative":{"exercise_price":7.9,"expiration_date":"2023-02-05","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-22-093748","document":"tm2223647-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465922093748/tm2223647-3_4seq1.xml","form_type":"4"}},{"id":2175936,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2022-08-23T21:16:08.000Z","date":"2022-08-22","kind":"sale","acquired":false,"shares":5000,"price":35.98,"value":179900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022."}],"balance_after":87220,"source":{"system":"sec-edgar","filing":"0001104659-22-093748","document":"tm2223647-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465922093748/tm2223647-3_4seq1.xml","form_type":"4"}},{"id":2175935,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2022-08-23T21:16:08.000Z","date":"2022-08-22","kind":"exercise","acquired":true,"shares":5000,"price":7.9,"value":39500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022."}],"balance_after":92220,"source":{"system":"sec-edgar","filing":"0001104659-22-093748","document":"tm2223647-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465922093748/tm2223647-3_4seq1.xml","form_type":"4"}},{"id":2192999,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-08-05T20:31:13.000Z","date":"2022-08-04","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested in four equal annual installments beginning on February 5, 2014."}],"balance_after":5000,"derivative":{"exercise_price":7.9,"expiration_date":"2023-02-05","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-22-086723","document":"tm2222645-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465922086723/tm2222645-2_4seq1.xml","form_type":"4"}},{"id":2192998,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2022-08-05T20:31:13.000Z","date":"2022-08-04","kind":"sale","acquired":false,"shares":5000,"price":32.98,"value":164900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022."}],"balance_after":87220,"source":{"system":"sec-edgar","filing":"0001104659-22-086723","document":"tm2222645-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465922086723/tm2222645-2_4seq1.xml","form_type":"4"}},{"id":2192997,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2022-08-05T20:31:13.000Z","date":"2022-08-04","kind":"exercise","acquired":true,"shares":5000,"price":7.9,"value":39500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022."}],"balance_after":92220,"source":{"system":"sec-edgar","filing":"0001104659-22-086723","document":"tm2222645-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465922086723/tm2222645-2_4seq1.xml","form_type":"4"}},{"id":2371554,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Restricted Stock Units","published_at":"2022-02-25T22:17:12.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-22-027398","document":"tm227764-5_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465922027398/tm227764-5_4aseq1.xml","form_type":"4/A","original_submission_date":"2022-02-24"}},{"id":2371553,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-02-25T22:17:12.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal annual installments beginning on February 22, 2023."}],"balance_after":18000,"derivative":{"exercise_price":32.2,"expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-22-027398","document":"tm227764-5_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465922027398/tm227764-5_4aseq1.xml","form_type":"4/A","original_submission_date":"2022-02-24"}},{"id":2374242,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Restricted Stock Units","published_at":"2022-02-25T02:22:26.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-22-026873","document":"tm227622-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465922026873/tm227622-11_4seq1.xml","form_type":"4"}},{"id":2374241,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-02-25T02:22:26.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal annual installments beginning on February 22, 2023."}],"balance_after":18000,"derivative":{"exercise_price":32.2,"expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-22-026873","document":"tm227622-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465922026873/tm227622-11_4seq1.xml","form_type":"4"}},{"id":2749387,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-04-15T00:24:13.000Z","date":"2021-04-14","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted March 11, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal annual installments beginning on March 1, 2017."}],"balance_after":6250,"derivative":{"exercise_price":12.98,"expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001104659-21-050369","document":"tm2113039-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465921050369/tm2113039-1_4seq1.xml","form_type":"4"}},{"id":2749386,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-04-15T00:24:13.000Z","date":"2021-04-13","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted March 11, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal annual installments beginning on March 1, 2017."}],"balance_after":9375,"derivative":{"exercise_price":12.98,"expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001104659-21-050369","document":"tm2113039-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465921050369/tm2113039-1_4seq1.xml","form_type":"4"}},{"id":2749385,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2021-04-15T00:24:13.000Z","date":"2021-04-14","kind":"sale","acquired":false,"shares":3125,"price":31.98,"value":99937.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted March 11, 2021."}],"balance_after":86326,"source":{"system":"sec-edgar","filing":"0001104659-21-050369","document":"tm2113039-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465921050369/tm2113039-1_4seq1.xml","form_type":"4"}},{"id":2749384,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2021-04-15T00:24:13.000Z","date":"2021-04-14","kind":"exercise","acquired":true,"shares":3125,"price":12.98,"value":40562.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted March 11, 2021."}],"balance_after":89451,"source":{"system":"sec-edgar","filing":"0001104659-21-050369","document":"tm2113039-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465921050369/tm2113039-1_4seq1.xml","form_type":"4"}},{"id":2749383,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2021-04-15T00:24:13.000Z","date":"2021-04-13","kind":"sale","acquired":false,"shares":3125,"price":29.9846,"value":93701.875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted March 11, 2021."}],"balance_after":86326,"source":{"system":"sec-edgar","filing":"0001104659-21-050369","document":"tm2113039-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465921050369/tm2113039-1_4seq1.xml","form_type":"4"}},{"id":2749382,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Common Stock","published_at":"2021-04-15T00:24:13.000Z","date":"2021-04-13","kind":"exercise","acquired":true,"shares":3125,"price":12.98,"value":40562.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted March 11, 2021."}],"balance_after":89451,"source":{"system":"sec-edgar","filing":"0001104659-21-050369","document":"tm2113039-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465921050369/tm2113039-1_4seq1.xml","form_type":"4"}},{"id":2838640,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-02-23T23:54:09.000Z","date":"2021-02-19","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal annual installments beginning on February 19, 2022."}],"balance_after":17000,"derivative":{"exercise_price":29.61,"expiration_date":"2031-02-19","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-21-026937","document":"tm217706-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465921026937/tm217706-9_4seq1.xml","form_type":"4"}},{"id":3248649,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":93800,"kind":"person","name":"Martin Tami Tillotson","position":1,"cik":"0001539494","reported_name":"Martin Tami Tillotson","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Regulatory Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-02-25T23:33:30.000Z","date":"2020-02-21","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in four equal annual installments beginning on February 21, 2021."}],"balance_after":22000,"derivative":{"exercise_price":23.99,"expiration_date":"2030-02-21","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001104659-20-024915","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465920024915/a4.xml","form_type":"4"}}]}